Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
$19.23
$0.28(1.32%)
At close: 4:00 PM EST
$19.23
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$12.30 - $23.77
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.79M
Market Cap
$3.05B
Enterprise Value$2.89B
Total Cash (Recent Filing)$867.88M
Total Debt (Recent Filing)$42.29M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 12, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding158,591,490
10 Day Avg. Volume1,610,759
30 Day Avg. Volume1,788,949
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-5.43
Forecast
1Y Price Target
$36.27Price Target Upside88.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.58
Revenue Forecast (FY)$58.31M
Bulls Say, Bears Say
Bulls Say
Biomarker-driven EfficacyStrong normalization of disease biomarkers with Avlayah demonstrates meaningful target engagement and suggests the therapy could deliver substantially improved patient outcomes compared with current standards.
Commercial Launch PotentialA broad pediatric label combined with an assembled commercial infrastructure and premium pricing supports a scalable launch and meaningful revenue upside if payer access is obtained.
Regulatory ValidationFDA accelerated approval of Avlayah for neurologic manifestations validates the company's brain‑delivery transport technology and supports a regulatory pathway for related pipeline programs.
Bears Say
Biology UncertaintyFailures in a comparable program and cautious pullback by a major partner highlight uncertainty about whether progranulin replacement will produce consistent clinical benefit in patients.
Financial And Execution RiskAssuming full responsibility for development and commercialization increases research and selling expenses and reduces the probability of success used in valuation, raising financial and execution risk.
Safety And Access HeadwindsA boxed warning for hypersensitivity, reports of membranous nephropathy and severe infusion reactions combined with reimbursement uncertainty could slow patient switching and delay revenue realization.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $12.30 and its highest was $23.77 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.05B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 29 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.737 by $0.007.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.66.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 158,591,490 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.737. Following the earnings report the stock price went down -1.12%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.27 (88.61% Upside)
$36.27 (88.61% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 965.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.84%
12-Months-Change
Fundamentals
Return on Equity
-50.13%
Trailing 12-Months
Asset Growth
-16.69%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
DNLI Stock 12 Month Forecast
Average Price Target
$36.27
▲(88.61% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
6.65% Insiders
24.31% Mutual Funds
34.00% Other Institutional Investors
19.56% Public Companies and
Individual Investors